Novel Drug Prolongs Survival in Men with Metastatic Prostate Cancer
SAN FRANCISCO—Cabazitaxel, a novel taxane, prolongs survival better than mitoxantrone in patients with metastatic castration-resistant prostate cancer (mCRPC) and who had failed previous treatment with docetaxel, according to new findings from a phase 3 trial presented here today at the Genituourinary Cancers Symposium.
